Displaying drugs 2051 - 2075 of 3480 in total
Brimapitide
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10 …
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
BMN-052
Experimental
Withdrawn
Pidacmeran
Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults).
Investigational
Matched Description: … trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 …
NX-1207
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Investigational
MORAb-066
MORAb-066 is a humanized antibody directed against tissue factor (TF). It is being investigated in pancreatic cancer.
Investigational
Zanzalintinib
Investigational
LB-001
LB-001 is a gene editing therapy designed to incorporate a functioning version of the faulty methylmalonyl-COA mutase (MUT) gene into the genome of patients with methylmalonic acidemia.
Investigational
RTL-1000
RTL-1000 is a recombinant T-Cell receptor ligand being investigated for the treatment of multiple sclerosis.
Investigational
Progerinin
Investigational
BMN-046
Experimental
Withdrawn
BMN-055
Experimental
Withdrawn
Cendakimab
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
Investigational
ONCOS-102
Investigational
Lumiflavin
Experimental
FBX-101
FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene
Investigational
Matched Description: … FBX-101 is an adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase …
MK-0668
Experimental
alpha-Hydroxylinoleic acid
alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).
Investigational
Mitoglitazone
Mitoglitazone has been used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.
Investigational
Chlorphenoxamine
Chlorphenoxamine is marketed under the name Phenoxene. It is an antihistamine and anticholinergic used to treat itching as well as for its antiparkinsonian effect.
Withdrawn
Matched Products: … SISTRAL 10 MG/ML ENJEKSİYONLUK ÇÖZELTİ, 6 ADET …
Evening primrose oil
Evening primrose oil comes from the extraction from Oenothera biennis seeds and it is commonly used as an alternative source for omega-6 essential fatty acids. In its composition it presents some fatty acids such as DB00132 and DB13854. Evening primrose oil has been filled for the FDA by Humanetics Corporation...
Investigational
Nutraceutical
Matched Mixtures name: … OGAMIX(Evening primrose oil 500 mg, Lecithin oil 500 mg, Fish oil 125 mgand Vitamin E 10 mg Soft Gelatin …
Matched Products: … Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA) ... Nn EVENING PRIMROSE OIL 500MG (with 10% GLA) …
Matched Products: … Nn EVENING PRIMROSE OIL 1000MG (with 10%GLA) ... Nn EVENING PRIMROSE OIL 500MG (with 10% GLA) …
Namitecan
Namitecan has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Iupac: … ^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione ... (19S)-10-[(1E)-[(2-aminoethoxy)imino]methyl]-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0 …
Loxicodegol
Loxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain . The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class...
Investigational
Matched Iupac: … [9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-17-ol ... (1S,5R,13R,14S,17S)-14-(2,5,8,11,14,17-hexaoxanonadecan-19-yloxy)-10-methoxy-4-methyl-12-oxa-4-azapentacyclo …
Displaying drugs 2051 - 2075 of 3480 in total